Skip to main content

CDK Gene Mutation

4
Pipeline Programs
5
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
5100%

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
1 program
1
AbemaciclibPhase 2Small Molecule
Prevail Therapeutics
1 program
1
AbemaciclibPhase 2Small Molecule1 trial
Active Trials
NCT03994796Active Not Recruiting50Est. Jun 2028
iN Therapeutics
iN TherapeuticsKorea - Gyeonggi
1 program
1
AbemaciclibPhase 2Small Molecule
Alliance Pharmaceuticals
1 program
1
AbemaciclibPhase 2Small Molecule
Kazia Therapeutics
Kazia TherapeuticsAustralia - Sydney
1 program
AbemaciclibPHASE_2Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Prevail TherapeuticsAbemaciclib

Clinical Trials (1)

Total enrollment: 50 patients across 1 trials

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Start: Oct 2019Est. completion: Jun 202850 patients
Phase 2Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.